TY - JOUR
T1 - Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis
AU - Kidd, Elizabeth A.
AU - Dehdashti, Farrokh
AU - Siegel, Barry A.
AU - Grigsby, Perry W.
PY - 2010/6
Y1 - 2010/6
N2 - Purpose: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUVmax) by positron emission tomography (PET) and its correlation with prognostic factors. Patients and methods: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET. Tumor histology included 65 squamous cell, 11 basaloid, and 1 small cell cancers. SUVmax and sites of lymph node metastasis were recorded. We analyzed the association between SUVmax and prognostic factors. Results: The mean SUVmax was 10.0 (range 1.0-43.1). The stage distribution included: 2 stage 0, 7 stage I, 49 stage II, 10 stage IIIA, 9 stage IIIB. SUVmax and clinical tumor size were not associated (R2 = 0.338). Histology did not significantly influence SUVmax (mean SUVmax 10.0 for squamous versus 9.90 for basaloid). Higher SUVmax was associated with an increased risk of nodal metastasis at diagnosis (p < 0.0001). Higher SUVmax was associated with worse disease-free survival (p = 0.05). Patients with high anal tumor SUVmax at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4 months after completing therapy (p = 0.0402). Conclusions: SUVmax is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
AB - Purpose: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUVmax) by positron emission tomography (PET) and its correlation with prognostic factors. Patients and methods: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET. Tumor histology included 65 squamous cell, 11 basaloid, and 1 small cell cancers. SUVmax and sites of lymph node metastasis were recorded. We analyzed the association between SUVmax and prognostic factors. Results: The mean SUVmax was 10.0 (range 1.0-43.1). The stage distribution included: 2 stage 0, 7 stage I, 49 stage II, 10 stage IIIA, 9 stage IIIB. SUVmax and clinical tumor size were not associated (R2 = 0.338). Histology did not significantly influence SUVmax (mean SUVmax 10.0 for squamous versus 9.90 for basaloid). Higher SUVmax was associated with an increased risk of nodal metastasis at diagnosis (p < 0.0001). Higher SUVmax was associated with worse disease-free survival (p = 0.05). Patients with high anal tumor SUVmax at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4 months after completing therapy (p = 0.0402). Conclusions: SUVmax is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
KW - Anal cancer
KW - F-18 fluorodeoxyglucose
KW - Positron emission tomography
KW - Prognosis
KW - Standardized uptake value
UR - http://www.scopus.com/inward/record.url?scp=77952581144&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2010.02.019
DO - 10.1016/j.radonc.2010.02.019
M3 - Article
C2 - 20231040
AN - SCOPUS:77952581144
SN - 0167-8140
VL - 95
SP - 288
EP - 291
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -